Table 3.
In vitro cytotoxicity of 2-aryl-6-substituted quinazolinones
| IC50 (μM) | |||||
|---|---|---|---|---|---|
| Compounds | M21 | CH27 | H460 | Hep3B | HSC-3 |
| 17 (MJ70) | 0.09 ± 0.006 | 0.09 ± 0.004 | 0.07 ± 0.02 | 1.94 ± 0.46 | 0.15 ± 0.03 |
| 18 (MJ74) | >10 | >10 | >10 | >10 | >10 |
| 19 (MJ79) | >10 | >10 | >10 | >10 | >10 |
| 20 (MJ69) | 0.63 ± 0.042 | 0.43 ± 0.03 | 4.37 ± 0.33 | 8.74 ± 0.63 | 0.20 ± 0.03 |
| 21 (MJ75) | >10 | >10 | >10 | >10 | >10 |
| 22 (MJ80) | >10 | >10 | >10 | >10 | >10 |
| 23 (MJ66) | 0.03 ± 0.005 | 0.05 ± 0.01 | 0.08 ± 0.01 | 1.35 ± 0.12 | 0.04 ± 0.003 |
| 24 (MJ65) | 7.94 ± 0.66 | 8.14 ± 0.53 | 8.89 ± 0.45 | 7.50 ± 0.55 | 2.01 ± 0.37 |
| 25 (MJ78) | >10 | >10 | >10 | >10 | 4.97 ± 0.82 |
| 26 (MJ68) | 0.44 ± 0.02 | 0.38 ± 0.01 | 0.38 ± 0.04 | 7.46 ± 0.90 | 1.65 ± 0.45 |
| 27 (MJ72) | 8.1 ± 0.57 | >10 | 6.86 ± 0.67 | 6.86 ± 0.81 | >10 |
| 28 (MJ73) | >10 | >10 | >10 | >10 | >10 |
| 29 (MJ67) | 0.49 ± 0.05 | 0.78 ± 0.07 | 0.44 ± 0.04 | 1.11 ± 0.14 | 0.63 ± 0.06 |
| 30 (MJ76) | >10 | >10 | >10 | >10 | >10 |
| 31 (MJ77) | >10 | >10 | >10 | >10 | >10 |
| HMJ38 | 3.44 ± 0.39 | >10 | >10 | >10 | 2.69 ± 0.38 |
Cell viability was determined by Trypan blue exclusion assay. The IC50 values of 2-aryl-6-substituted quinazolinones were determined from dose–response curves. All results are expressed as the mean percentage of control ± SD of triplicate determinations from three independent experiments.
CH27, human lung squamous carcinoma; H460, human lung non-small carcinoma cells; Hep3B, human hepatoma; HSC-3, human oral cancer cells; M21, human malignant melanoma.